Publications

Detection of mcr-1 among Escherichia coli clinical isolates collected worldwide as part of the SENTRY Antimicrobial Surveillance Program during 2014-2015. by Castanheira M, Griffin MA, Deshpande LM, Mendes RE, Jones RN and Flamm RK published in Antimicrob. Agents. Chemother. 2016; 60 (9): 5623-5624

High rates of nonsusceptibility to ceftazidime-avibactam and identification of New Delhi metallo-β-lactamase production in Enterobacteriaceae bloodstream infections at a major cancer center. by Aitken SL, Tarrand JJ, Deshpande LM, Tverdek FP, Jones AL, Shelburne SA, Prince RA, Bhatti MM, Rolston KV, Jones RN, Castanheira M and Chemaly RF published in Clin. Infect. Dis. 2016; 63 (7): 954-958

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2014-2016) P. aeruginosa Isolates from Hospitalized Patients with Bloodstream Infections and Pneumonia in European Medical Centres. Lead author: D Shortridge, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1246

Telavancin Activity against a Global Collection of Staphylococcus aureus Clinical Isolates (2013-2015). Lead author: RE Mendes, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1356

β-lactamase Characterization of Baseline Gram-Negative Pathogens from a Phase 3 Trial of Ceftazidime-Avibactam (CAZ-AVI) for the Treatment of Nosocomial Pneumonia. Lead author: RE Mendes, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P0408

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2014-2016) Gram-Negative Organisms Collected from European Medical Centres. Lead author: D Shortridge, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1271

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2014-2016) Gram-Negative Organisms Collected from Latin America Medical Centres. Lead author: LR Duncan, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1272

Dalbavancin Tested against Staphylococcus aureus Isolates with Decreased Susceptibility to Glycopeptides and/or Lipopeptides from European Hospitals (2012-2016). Lead author: RE Mendes, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna Austria
# P0138

Activity of Tedizolid against Methicillin-Susceptible and -Resistant Staphylococcus aureus Pathogens Isolated from Patients in European Centres and Surrounding Regions. Lead author: RE Mendes, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1344

Activity of Tedizolid against Gram-Positive Clinical Isolates Causing Infections in Europe and Surrounding Areas (2014-2015). Lead author: RE Mendes, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1502

Plazomicin Activity against European Enterobacteriaceae Isolates Carrying Aminoglycoside-Modifying Enzymes and 16S rRNA Methylases. Lead author: M Castanheira, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1281

In vitro Activity of Omadacycline and Comparators against Staphylococci, and Enterococci (including resistant organism subsets) from Patients in European medical Centres during 2016: Results from the SENTRY Antimicrobial Surveillance Program. Lead author: MD Huband, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1262

In vitro Activity of Omadacycline and Comparators against Gram-Negative Bacterial Isolates Collected from Patients in European Medical Centres (2016): Results from the SENTRY Antimicrobial Surveillance Program. Lead author: MD Huband, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1253

Meropenem-Vaborbactam Activity against Enterobacteriaceae Isolates Collected during 2014-2015 from European Countries. Lead author: M Castanheira, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1286

Monitoring Echinocandin and Azole Susceptibility in a Global Collection of Invasive Fungal Isolates. Lead author: M Castanheira, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, 2017, Vienna, Austria
# P1748

In vitro Evaluation of Delafloxacin Activity When Tested against Contemporary ABSSSI Isolates from Europe and Surrounding Areas (2014-2016): Results from the SENTRY Antimicrobial Surveillance Program. Lead author: MD Huband, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1351

Dalbavancin Tested against Staphylococcus aureus Isolates with Decreased Susceptibility to Glycopeptides and/or Lipopeptides from European Hospitals (2012-2016). Lead author: RE Mendes, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, 2017, Vienna, Austria
# P0138

Antimicrobial Activity of Ceftobiprole versus Other Currently Marketed Cephalosporins and β-Lactams When Tested against Contemporary Gram-Positive and -Negative Organisms Collected from Europe (2015). Lead author: RK Flamm, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P0146

Antimicrobial Activity of Ceftazidime-Avibactam Tested against Contemporary (2013-2015) Gram-Negative Organisms Collected from United States Medical Centers. Lead author: HS Sader, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, Vienna, Austria
# P1291

Activity of Plazomicin and Comparator Agents Tested against Recent Clinical Isolates Collected in Asia-Pacific, Europe, and Latin America. Lead author:M Castanheira, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, April 22-26, 2017, Vienna, Austria
# P1280

Ceftaroline Activity against MDR Streptococcus pneumoniae Subsets from United States Medical Centers (2014), Lead author: Farrell DJ, presented at American Thoracic Society 2016 (ATS 2016), May 13-18, 2016, San Francisco, California, USA
Poster A2117

Serotype Distribution of Streptococcus pneumoniae Recovered from Adults in the United States and Selected European Countries (2009-2013), Lead author: Mendes RE, presented at 10th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-10), June 26-30, 2016, Glasgow, Scotland

Ceftazidime-avibactam Activity against P. aeruginosa from Intensive Care (ICU) and Non-ICU Patients, Lead author: Sader HS, presented at Society of Critical Care Conference, 46th Critical Care Congress, January 21-25, 2017, Honolulu, Hawaii, USA

Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria from ICU Patients with Pneumonia, Lead author: Sader HS, presented at Society of Critical Care Conference, 46th Critical Care Congress, January 21-25, 2017, Honolulu, Hawaii, USA

Surveillance of Ceftolozane/Tazobactam Antimicrobial Activity Tested Against Contemporary Gram-Negative Organisms and Streptococcus pneumoniae Isolated in Australia

Analysis of MIC Relationships Between Tedizolid, Linezolid, and Vancomycin Tested Against Staphylococcus aureus and Enterococcal Clinical Isolates from US and European Hospitals (2014-2015), Lead author: Mendes RE, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1829

In Vitro Activity of Tedizolid in Comparison With Other Oral and Intravenous Agents Against a US Collection of Community-Acquired Methicillin-Resistant Staphylococcus aureus (2014-2015), Lead author: Mendes RE, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1821

Activity of Pexiganan when Tested against Contemporary Gram-Positive, Gram-Negative Bacteria and Yeast Collected from North America, Europe and Japan, Lead author: Flamm, RK, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1826

Prevalence of Main Gram-positive Pathogens Causing Bloodstream Infections in US Medical Centers (2010-2015) and Analysis of Oritavancin In Vitro Activity, Lead author: Mendes RE, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 303

Activity of Omadacycline when Tested against Gram-Positive Bacteria Isolated from Patients in the USA During 2015 as Part of a Global Surveillance Program, Lead author: Flamm, RK, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1827

Activity of Linezolid when Tested against Gram-Positive Isolates from the USA (Linezolid Experience and Accurate Determination of Resistance [LEADER]) from 2015, Lead author: Flamm RK, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 2007

Activity of Isavuconazole and Comparator Mould-Active Triazoles Tested against Contemporary Invasive Mould Isolates, Lead author: Pfaller MA, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1621

In Vitro Activity of ZTI-01 (Fosfomycin for Injection) against Contemporary Gram-negative and Gram-positive Isolates – A Comparison of Inter-method Testing, Lead author: Flamm RK, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1833

Activity of Dalbavancin Tested against Gram-positive Clinical Isolates Causing Skin and Skin Structure Infections in Pediatric Patients from USA Hospitals (2014-2015), Lead author: Mendes RE, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1835

Dalbavancin In Vitro Activity Obtained against Gram-positive Clinical Isolates Causing Bone and Joint Infections in USA and European Hospitals (2011-2015), Lead author: Mendes RE, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1834

Next Generation Sequencing for Genomic Analysis of Cfr(B)-producing Enterococcus faecium Causing Infections in a New Orleans Medical Center, Lead author: Deshpande L, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1408

Evaluation of the In Vitro Activity of Ceftaroline Tested against Clinical Bacterial Isolates from USA Hospitals: Results from 5 Years of the AWARE Surveillance Program (2011-2015), Lead author: Sader HS, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1846

Activity of a Long-Acting Echinocandin (CD101) and Comparator Antifungal Agents Tested Against Contemporary Worldwide Invasive Fungal Isolates, Lead author: Pfaller MA, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1625

Antimicrobial Activity of Ceftazidime-Avibactam Tested Against Pseudomonas aeruginosa Isolates from USA Hospitals Stratified by Site of Infection: Results from the INFORM Surveillance Program, 2013-2015, Lead author: Sader HS, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1831

Ceftazidime-Avibactam Activity when Tested against Gram-negative Bacteria Isolated from Patients with Pneumonia, Including Ventilator-Associated Pneumonia (VAP), Hospitalized in United States Medical Centers (2011-2015), Lead author: Sader HS, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1837

Ceftazidime-Avibactam Antimicrobial Activity and Spectrum when Tested against Gram-Negative Organisms from Pediatric Patients: Results from the INFORM Surveillance Program (USA, 2011-2015), Lead author: Sader HS, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 703

Antimicrobial Susceptibility of KPC-Producing Enterobacteriaceae Stratified by Infection Site (USA, 2012-2015), Lead author: Castanheira M, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1850

Ceftolozane/Tazobactam Activity Tested Against Bacterial Bloodstream Isolates from Multiple Infection Sources, Lead author: Shortridge D, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1824

Activity of Ceftolozane/Tazobactam and Comparators Tested Against Carbapenem-Nonsusceptible Pseudomonas aeruginosa Isolates, Lead author: Shortridge D, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 1823

Serotype Distributions and Analysis of Susceptibility Profiles of Streptococcus pneumoniae Causing Infections in Adult Patients in the United States (2009-2013), Lead author: Mendes RE, presented at ID Week 2016, October 26-30, 2016, New Orleans, LA, USA
Poster 786

In Vitro Antibacterial Activity of WCK 5999: A New Carbapenem/β-lactamase Inhibitor Combination against ESBL-Phenotype and Carbapenemase Producing Enterobacteriaceae from a Worldwide Surveillance Program (2015), Lead author: Huband M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Monday-425

Activity of the New Carbapenem/β-Lactamase Inhibitor Combination WCK 5999 against Gram-Negative Isolates Producing Oxacillinases (OXAs), Lead author: Castanheira M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Monday-422

In Vitro Activity of WCK 5999, a Carbapenem/β-lactamase Inhibitor Combination Tested against Contemporary KPC-producing Enterobacteriaceae, Lead author: Castanheira M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Monday-421

In Vitro Activity of WCK 5999 against Acinetobacter baumannii and Pseudomonas aeruginosa isolates from a Worldwide Surveillance Program (2015), Lead author: Huband M, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Friday-476

WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity Tested against Gram-negative Organisms Producing Clinically Relevant β-Lactamases, Lead author: Sader HS, presented at 1st annual American Society for Microbiology General Meeting (MICROBE), June 16 – 20, 2016, Boston, Massachusetts, USA
Sunday-447